Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Cancers|October 27, 2022
Endocrine and Neuroendocrine Tumors: A Special IssueAlfredo Berruti, Vito Amoroso, Nicola Fazio
Expert Opinion on Investigational Drugs|July 26, 2014
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumorsAndrea Giustina, Gherardo Mazziotti, Filippo Maffezzoni, et al.
Tumori|November 10, 2025
Selpercatinib plus cemiplimab in <i>RET</i> positive medullary thyroid cancer patient with skin cancersLaura Deborah Locati, Federica Puce, Vito Amoroso, et al.
Cancer Treatment Reviews|August 15, 2017
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysisElisa Roca, Cristina Gurizzan, Vito Amoroso, et al.
The Journal of Surgical Research|January 30, 2019
Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving SurgeryGiacomo Pata, Annamaria Guaineri, Anna Bianchi, et al.
Tumori|February 11, 2012
Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trialFrancesca Consoli, Salvatore Grisanti, Vito Amoroso, et al.
Endocrine|June 4, 2020
Should everolimus be stopped after radiological progression in metastatic insulinoma? A "cons" point of viewValeria Tovazzi, Vittorio D Ferrari, Alberto Dalla Volta, et al.
Frontiers in Oncology|August 21, 2024
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case reportElena Fassi, Vito Amoroso, Deborah Cosentini, et al.
BMC Cancer|June 2, 2007
Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteriaVito Amoroso, Frida Pittiani, Salvatore Grisanti, et al.
Breast (Edinburgh, Scotland)|November 7, 2024
Adjuvant denosumab for early breast cancer-Evidence and controversyLaura Moretti, Laura Richelmi, Deborah Cosentini, et al.
Pageof 6